Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection Go to Publication You Might Also Like Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. March 6, 2016 ‘Universal’ access for MDR-TB limited without the involvement of the private sector. January 10, 2011 Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. January 31, 2009 Corrigendum to “Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables” [Int. J. Mycobacteriol. 5(1) 2016 1-6]. September 5, 2016 Tuberculosis in South Asia: a tide in the affairs of men. March 22, 2018
Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. March 6, 2016
‘Universal’ access for MDR-TB limited without the involvement of the private sector. January 10, 2011
Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. January 31, 2009
Corrigendum to “Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables” [Int. J. Mycobacteriol. 5(1) 2016 1-6]. September 5, 2016